another vaccine developed by glaxo smith klein is based on a cold virus and is being tested in the united states and the u.k. results from that are expected before the end of the year. but ten thousand doses are being prepared to be sent to west africa if it's shown to be effective and safe. johnson and johnson is also developing a vaccine to be tested early next year. it requires two injections. one to prime the immune system and the other to boost it. the company says the vaccine can be manufactured quickly because every component can be produced separately. >>> quarantining ebola sufferers is still the most effective way to stop its spread but in west africa itself doing so means cutting off already poor people from their source of income. it's usually so busy here but now it's deserted. shops closed indefinitely and farmers who usually are here stay away. more than 20 homes in the town are cordened off under quarantine. all people lives in households where someone has died of ebola or had contact with a person confirmed as positive are required to stay inside their homes for 21 days.

. >>> glaxo-smith klein has received the green light to test the experimental ebola vaccine. some of those who will receive it are health workers headed for west africa where the virus has killed the largest number of people so far. it's based on a genetically modified chimp virus. >>> afghan president is in china right now. here's more from kabul. >>reporter: china is afghanistan's biggest business investor. thanks to a $3 billion deal for the rights to this copper-rich area outside kabul. but there are no chinese miners here. the roads and railways have not started. security concerns have stalled the project. in china, the president of afghanistan is hoping to revive this deal and chinese investment in his country's minerals worth annest meated $1 trillion. afghanistan wants chinese products. he travels to china once a year to buy goods shipped through neighboring pack stand. he hopes someday they'll arrive by truck. >> we can make a route from afghanistan directly to china. this is the first of what we need for the future. >>reporter: but the border is in a remote corner o

one is tested by pharmaceutical giant glaxo smith klein, the other by canada's agency. >> quarantiningbola sufferers is an effective way. doing so means cutting off more people from their income. >> in junction in sierra leone is a busy trading hub. now it's deserted. shops are closed, and farmers that come to the town's market to sell fruit and vegetables are staying away. >> some people die because of hunger. because of poverty, not to ebola, no more. they are hungry. >> reporter: more than 20 homes in the town are cordoned off, under quarantine. all people lying in households where someone -- living in households where someone died or who have had contact with someone who is positive are required to stay in their homes for 21 days, a measure health officials hope will stop the virus spreading. it comes at a price. >> aid groups have been supplying food to some of those understand quarantine, for many who are poor, it's been a desperate time. alfred recovered from the virus, to find 12 of his family members had died. >>> in neighbouring liberia, the president fears ebola will result

and canada, but the british pharmaceutical company glaxo smith klein has told the bbc that the vaccineen developing won't be fully ready for at least a year. and it will not be the solution to the current outbreak. simon cox went to the gsk lab to find out why. >> reporter: try as they might to stop its spread, ebola still has the upper hand. some experts believe the only way to contain it is with a vaccine. gsk is one of the companies fast-tracking an ebola vaccine, trying to shrink ten years of development into one. but they warn it still won't be ready in time to solve the current outbreak. >> we have to have data on its efficacy. that will not be available until after the end of 2015. we have to be able to make doses consistent with general use and that's going to take well into 2016 to be able to do that. so unfortunately it's not going to be as quickly as we would like. >> trials have already begun with volunteers receiving the drug, but there are no guarantees it will work. the next stage of testing is to offer 20,000 doses of the vaccine to health workers in the new year. until

w glaxo and smith klein is currently testing a vaccine for ebola. great to have you with us. i wonder if you could describe how did glaxo smith kline become associated with this attempt to find a vaccine for ebola? >> of course. thank you. and it is a pleasure to be here. in 2013 we purchased a company called ocaris. they had an ebola vaccine in the works. so in august of this year once the ebola crisis became epic proportions, the world health organization came to us and asked if we would attempt to phase them into trials. >> so that's where it is now, phase one trials? >> that's correct. human trials to test for safety. >> what's the time-line for this trial? >> there are four trials happening concurrently. there are two in the u.s. being sponsored by nih. one also in oxford, england. two more trials are happening in west africa. we expect to get the data from the phase one trials to be completed by the end of this year. hopefully based on the data, we will go into phase two trials in early 2015. >> donna, just to give people an understanding of the kind of distribution netw

vaccines are being worked on at glaxo smith klein. the patient is in serious condition.ecting an update later today in the news briefing. >> thank you very much. meg tir rel will bring us updates as we know more. >>> the national manufacturers association is kicking off its third annual manufacturing day today. president obama will be at the millennium steel plant in indiana. joining us right now first on cnbc is doug oberhelm. and joining us is jay timmons. welcome to both of you. it's great to see you. >> great to see you and good morning. we are celebrating today around the country and certainly here in washington with the nam board meeting. >> so the national manufacturers day. this is a day where what happens? you're trying to say these are great jobs. jay? >> opening their doors all over their countries. opening their doors to students and young people to show them all the possibilities that exist in manufacturing. there are still 600,000 jobs in manufacturing in this country that are open. we need people with the right skills to fill those jobs. >> i know the aver

. >> one more question on the vaccine, glaxo smith klein working on this thing, 10,000 viles right nows. they are rushing it to market as fast as they can. >> it's 100% effective in primates. they gave it to 20 people in phase one. it looks good and is getting ready to go to phase two. it is probably about six months away from use in everybody, the large scale use. i think it's a ticket and could be a game-changer. >> dr. siegal, great to see you. >> great to see you. >>> other stories making headlines this sunday morning, we start with the fox news alert breaking overnight. baghdad under siege. news of a triple homicide bombing just outside the iraqi capital. at least 22 people are dead and dozens more injured in a kurdish security compound northeast of the city of diyala. a homicide bomber set off a bomb at the entrance and two more explosives were in cars driven into the come pound. this as militants aim for the capital and to compromise the baghdad airport. >> i don't know how to make it clearer, if the airport falls to isis, it's game over. iraq no longer exists as a viable countr